Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +37.87%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +22.25%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.41%
#8 Songbird Songbird +12.58%
#9 Glidr Glidr +11.83%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.69%
Coin of the day
Helium Helium
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang in Aktien #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aktienkurs
$9.50
Zuletzt synchronisiert: 2025-01-08
Marktkapitalisierung
$819.52M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Kategorie

Healthcare
Operative Marge für Poseida Therapeutics, Inc. (PSTX)
Operative Marge zum August 2026 TTM: -200.15%
Laut den neuesten Finanzberichten und dem Aktienkurs von Poseida Therapeutics, Inc. beträgt die aktuelle operative Marge (TTM) -200.15%. Am Ende des Jahres 2022 lag die operative Marge bei -45.98%.
Historie der operativen Marge von Poseida Therapeutics, Inc. von 2016 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -200.15% 0.00%
2023 -200.15% 335.30%
2022 -45.98% -89.84%
2021 -452.69% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% -100.00%
2017 -658.89% 1,081.23%
2016 -55.78% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.19%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.14%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.13%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.26%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.